Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.

Patrick Coffie 1, 2, 3 Besigin Tonwe-Gold 1, 2, 3 Aristophane Tanon 4 Clarisse Amani-Bosse 3 Gédéon Bédikou 3 Elaine Abrams 5 François Dabis 1, 2 Didier Ekouevi 1, 2, 3, *
* Auteur correspondant
1 Epidémiologie et Biostatistique [Bordeaux]
2 ISPED - Institut de Santé Publique, d'Epidémiologie et de Développement
3 ACONDA - MTCT-Plus programme
4 Service des maladies infectieuses et tropicales
5 MTCT-Plus Initiative
Abstract : BACKGROUND: In resource-limited settings where nevirapine-containing regimen is the preferred regimen in women, data on severe adverse events (SAEs) according to CD4 cell count are limited. We estimated the incidence of SAEs according to CD4 cell count and identify their risk factors in nevirapine-treated women. METHODS: All HIV-infected women who initiated nevirapine-containing regimen in the MTCT-Plus operational program in Abidjan, Côte d'Ivoire, were eligible for this study. Laboratory and clinical (rash) SAEs were classified as grade 3 and 4. Cox models were used to identify factors associated with the occurrence of SAEs. RESULTS: From August 2003 to October 2006, 290 women initiated a nevirapine-containing regimen at a median CD4 cell count of 186 cells/mm3 (IQR 124-266). During a median follow-up on treatment of 25 months, the incidence of all SAEs was 19.5/100 patient-years. The 24-month probability of occurrence of hepatotoxicity or rash was not different between women with a CD4 cell count >250 cells/mm3 and women with a CD4 cell count 250 cells/mm3 at treatment initiation nor initiation NVP-based regimen initiated during pregnancy were associated with the occurrence of SAEs. CONCLUSION: CD4 cell count >250 cells/mm3 was not associated with a higher risk of severe hepatotoxicity and/or rash, as well as initiation of ART during pregnancy. Pharmacovogilance data as well as meta-analysis on women receiving NVP in these settings are needed for better information about NVP toxicity.
Type de document :
Article dans une revue
BMC Infectious Diseases, BioMed Central, 2010, 10, pp.188. 〈10.1186/1471-2334-10-188〉
Liste complète des métadonnées

Littérature citée [24 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-00521956
Contributeur : Evelyne Mouillet <>
Soumis le : mercredi 29 septembre 2010 - 10:32:07
Dernière modification le : mercredi 29 novembre 2017 - 14:54:15
Document(s) archivé(s) le : jeudi 30 décembre 2010 - 02:39:49

Fichier

Coffie_188.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

Citation

Patrick Coffie, Besigin Tonwe-Gold, Aristophane Tanon, Clarisse Amani-Bosse, Gédéon Bédikou, et al.. Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.. BMC Infectious Diseases, BioMed Central, 2010, 10, pp.188. 〈10.1186/1471-2334-10-188〉. 〈inserm-00521956〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

160

Téléchargements de fichiers

544

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD